Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

CTXR

Citius Pharmaceuticals Inc

Jan 02 • 04:00PM ET

0.8480

+0.0710 9.14 %

Healthcare • Biotechnology • USA • NASD

Peers: EBS GERN ADMA XOMA ANIP PTGX SCYX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.81	Insider Own	2.67%	Shs Outstand	20.76M	Perf Week	5.92%
Market Cap	17.61M	Forward P/E	0.27	EPS next Y	3.10	Insider Trans	0.00%	Shs Float	20.21M	Perf Month	-32.70%
Enterprise Value	25.15M	PEG	-	EPS next Q	0.43	Inst Own	10.04%	Short Float	13.00%	Perf Quarter	-36.24%
Income	-37.43M	P/S	-	EPS this Y	156.21%	Inst Trans	-1.27%	Short Ratio	2.18	Perf Half Y	-61.63%
Sales	0.00M	P/B	0.23	EPS next Y	63.16%	ROA	-30.21%	Short Interest	2.63M	Perf YTD	9.14%
Book/sh	3.74	P/C	4.14	EPS next 5Y	-	ROE	-54.40%	52W High	4.51 -81.20%	Perf Year	-78.31%
Cash/sh	0.20	P/FCF	-	EPS past 3/5Y	16.24% 21.29%	ROIC	-54.83%	52W Low	0.63 34.60%	Perf 3Y	-95.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.13% 12.08%	Perf 5Y	-96.94%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	35.89%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.13	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.04	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.62	EPS Q/Q	72.28%	SMA20	-17.09%	Beta	1.60	Target Price	6.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-29.16%	Rel Volume	0.35	Prev Close	0.78
Employees	23	LT Debt/Eq	0.01	Earnings	Dec 25 AMC	SMA200	-29.41%	Avg Volume	1.21M	Price	0.85
IPO	Oct 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	97.67% -	Trades		Volume	426,342	Change	9.14%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Upgrade	D. Boral Capital	Hold → Buy	$9
Nov-30-21	Initiated	Maxim Group	Buy	$4

Dec-23-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) -23.02%
04:30PM	Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire)
Dec-09-25 08:30AM	Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +7.14%
Dec-04-25 08:37AM	Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim (PR Newswire) +9.17%
Dec-01-25 12:00PM	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire) -6.25%
08:37AM	Loading…
Nov-21-25 08:37AM	Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration (PR Newswire) +15.15%
Oct-21-25 04:30PM	Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -7.18% -6.55%
08:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-20-25 08:37AM	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch (PR Newswire) +24.83%
Oct-17-25 05:00PM	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire)
Oct-16-25 08:47AM	Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR (PR Newswire) +6.47%
Sep-10-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Sep-09-25 08:30AM	Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Aug-22-25 08:47AM	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch (PR Newswire) +9.76%
Aug-12-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
04:30PM	Loading…
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Jul-17-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire) +7.05%
Jul-16-25 09:15AM	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire) -8.59%
Jul-15-25 08:32AM	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora (PR Newswire)
Jul-08-25 08:34AM	Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -8.08%
Jul-06-25 04:01AM	Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR (Insider Monkey)
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire) +8.00%
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire) -8.91%
08:35AM	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jun-10-25 07:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -22.63%
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +60.99%
May-14-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire) +19.20% -11.74%
May-05-25 08:37AM	Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (PR Newswire) +5.33%
Apr-01-25 09:00AM	Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock (PR Newswire) -19.46%
Feb-14-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -8.18%
08:55AM	Loading…
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire)
Jan-08-25 08:00AM	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire) -15.10%
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) +11.76%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire)
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-30-24 09:43AM	American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls (The Fly) +6.25%
Dec-29-24 10:50PM	Citius Pharma Reports 2024 Financial Results and Business Update (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +11.18% +6.25%
Nov-25-24 08:03AM	Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval (PR Newswire)
Nov-22-24 09:00AM	Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split (PR Newswire) -18.96%
Nov-18-24 04:05PM	Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering (PR Newswire) +12.10% -14.45%
Nov-15-24 01:30PM	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering (PR Newswire) -39.10%
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +9.16%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)
Aug-13-24 09:30AM	Sidoti Events, LLC's Virtual August Micro-Cap Conference (ACCESSWIRE) -11.69%
04:32AM	Citius merges oncology subsidiary with TenX Keane (Pharmaceutical Technology)
Aug-12-24 10:53PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024 (InvestorPlace) -11.38%
05:28PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
04:22PM	Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. (PR Newswire)
08:00AM	Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments (PR Newswire)
Aug-09-24 07:30AM	TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update (GlobeNewswire) -12.36%
Aug-08-24 05:41PM	Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection (Benzinga)
06:59AM	Citius Pharmaceuticals Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Aug-05-24 08:00AM	TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals (GlobeNewswire)
08:00AM	Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. (PR Newswire)
Jul-18-24 07:00AM	Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL) (Newsfile)
Jul-17-24 08:00AM	Analysts Hunt for Undervalued Biotech Stocks (Newsfile)
Jul-11-24 11:00AM	Bloodstream Infections - From Threats to Solutions (Newsfile)
08:00AM	Biopharma Stocks Transformative Innovation for the Future of Health (Newsfile)
Jul-10-24 09:10AM	Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates (PR Newswire) +10.29%
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
May-29-24 08:30AM	Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-21-24 11:42AM	Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue (InvestorPlace) +10.64%
11:20AM	VFS Stock Alert: VinFast Plunges on NHTSA Probe (InvestorPlace)
10:58AM	Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today? (InvestorPlace)
07:00AM	Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-14-24 10:55PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024 (InvestorPlace) -9.15%
04:05PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-10-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences (PR Newswire)
Apr-30-24 04:05PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire) +7.85%
Apr-26-24 10:43AM	Citius Pharmaceuticals Launches $15 Million Offering (MT Newswires) -9.25%
08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire)
Apr-11-24 08:30AM	Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma (PR Newswire)
Apr-04-24 08:30AM	Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference (PR Newswire)
Mar-18-24 08:30AM	Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-07-24 08:30AM	Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program (PR Newswire)
Feb-26-24 07:30AM	Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration (PR Newswire)
Feb-23-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences (PR Newswire)
Feb-15-24 09:17AM	Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials (GuruFocus.com) +9.12%
Feb-14-24 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update (PR Newswire) +13.51%
08:01AM	Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Jan-23-24 08:30AM	Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors (PR Newswire)
Jan-02-24 08:31AM	Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters (PR Newswire) +6.90%
08:30AM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-09-23 08:30AM	Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 (PR Newswire)
Oct-31-23 08:45AM	Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR in Combination with Checkpoint Inhibitor (PR Newswire)
Oct-24-23 07:30AM	Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. (PR Newswire) +17.36%
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-18-23 04:30PM	Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 (PR Newswire)
Sep-13-23 04:30PM	Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir (PR Newswire) -6.48%
Sep-08-23 08:00AM	Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR (PR Newswire)
Sep-06-23 04:30PM	Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 (PR Newswire) -5.25%
Aug-14-23 04:15PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -6.66%
Aug-10-23 08:37AM	Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial (PR Newswire) +8.20%
Jul-29-23 04:16PM	Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTXR

Citius Pharmaceuticals Inc

Upgrade your FINVIZ experience